omniture

Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008

2008-10-27 21:41 1665

NANJING, China, Oct. 27 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today its participation in the Goldman Sachs China Investment Frontier Conference 2008. The conference will be held at the Grand Hyatt Beijing hotel on November 3-4, 2008.

Simcere's chief executive officer, Jinsheng Ren, chief financial officer, Frank Zhigang Zhao, and vice president of marketing, Mark Chen, will attend the conference on Thursday November 4. Jinsheng Ren will speak at the Track I Panel session headlined Healthcare: Reform of the Healthcare System: Impact and Likely Winners, which will take place on November 4, between 08:00-09:00 Beijing time. Later that afternoon, Frank Zhigang Zhao will give a company presentation to investors between 16:30-17:30.

A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com .

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 39 principal pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

For investor and media inquiries, please contact:

In Nanjing:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556-6666 ext. 8818

Email: ir@simcere.com

In Beijing:

Kejia Wu

Brunswick Group

Tel: +86-10-6566-4651

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5033

In New York:

Michael Guerin

Brunswick Group LLC

Tel: +1-212-333-3810

Source: Simcere Pharmaceutical Group
Related Stocks:
NYSE:SCR
collection